PL2295414T3 - Związek uracylu o aktywności hamującej ludzką trifosfatazę deoksyurydyny lub jego sól - Google Patents

Związek uracylu o aktywności hamującej ludzką trifosfatazę deoksyurydyny lub jego sól

Info

Publication number
PL2295414T3
PL2295414T3 PL09758110T PL09758110T PL2295414T3 PL 2295414 T3 PL2295414 T3 PL 2295414T3 PL 09758110 T PL09758110 T PL 09758110T PL 09758110 T PL09758110 T PL 09758110T PL 2295414 T3 PL2295414 T3 PL 2295414T3
Authority
PL
Poland
Prior art keywords
salt
inhibitory activity
uracil compound
deoxyuridine triphosphatase
human deoxyuridine
Prior art date
Application number
PL09758110T
Other languages
English (en)
Inventor
Masayoshi Fukuoka
Tatsushi Yokogawa
Seiji Miyahara
Hitoshi Miyakoshi
Wakako Yano
Junko Taguchi
Yayoi Takao
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of PL2295414T3 publication Critical patent/PL2295414T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL09758110T 2008-06-03 2009-06-02 Związek uracylu o aktywności hamującej ludzką trifosfatazę deoksyurydyny lub jego sól PL2295414T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008146334 2008-06-03
PCT/JP2009/002481 WO2009147843A1 (ja) 2008-06-03 2009-06-02 ヒトデオキシウリジントリホスファターゼ阻害活性を有する新規ウラシル化合物又はその塩
EP09758110A EP2295414B1 (en) 2008-06-03 2009-06-02 Uracil compound having inhibitory activity on human deoxyuridine triphosphatase or salt thereof

Publications (1)

Publication Number Publication Date
PL2295414T3 true PL2295414T3 (pl) 2013-02-28

Family

ID=41397926

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09758110T PL2295414T3 (pl) 2008-06-03 2009-06-02 Związek uracylu o aktywności hamującej ludzką trifosfatazę deoksyurydyny lub jego sól

Country Status (21)

Country Link
US (1) US8530490B2 (pl)
EP (1) EP2295414B1 (pl)
JP (1) JP4688975B2 (pl)
KR (1) KR101384940B1 (pl)
CN (1) CN102056905B (pl)
AU (1) AU2009254656B2 (pl)
BR (1) BRPI0913590B1 (pl)
CA (1) CA2726579C (pl)
CY (1) CY1113244T1 (pl)
DK (1) DK2295414T3 (pl)
ES (1) ES2392220T3 (pl)
HK (1) HK1154385A1 (pl)
HR (1) HRP20120820T1 (pl)
MX (1) MX2010013275A (pl)
MY (1) MY149180A (pl)
PL (1) PL2295414T3 (pl)
PT (1) PT2295414E (pl)
RU (1) RU2495873C2 (pl)
SI (1) SI2295414T1 (pl)
TW (1) TWI466871B (pl)
WO (1) WO2009147843A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY161094A (en) * 2009-11-30 2017-04-14 Taiho Pharmaceutical Co Ltd Anti-tumor effect potentiator
CA2830324A1 (en) * 2011-03-31 2012-10-04 Konstanze Schafer Perfluorinated compounds for non-viral transfer of nucleic acids
CN105189478B (zh) * 2013-01-07 2019-10-22 南加州大学 脱氧尿苷三磷酸酶抑制剂
US9790214B2 (en) 2014-01-03 2017-10-17 University Of Southern California Heteroatom containing deoxyuridine triphosphatase inhibitors
US20180110780A1 (en) * 2015-04-30 2018-04-26 Taiho Pharmaceutical Co., Ltd. Agent for alleviating side effect of antitumor drug
BR112017023649A2 (pt) * 2015-05-01 2018-07-17 Taiho Pharmaceutical Co., Ltd. novo cristal de composto de uracila
WO2017006270A1 (en) * 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
EA037990B1 (ru) 2015-07-08 2021-06-21 Св6 Терапьютикс (Най) Лимитед Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
MA43590A (fr) 2016-01-08 2018-11-14 Taiho Pharmaceutical Co Ltd Agent antitumoral contenant un immunomodulateur et un amplificateur d'effet antitumoral
WO2018098204A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
US10829457B2 (en) 2016-11-23 2020-11-10 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098206A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
WO2018098207A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11247984B2 (en) 2017-01-05 2022-02-15 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
CN115843249A (zh) 2020-06-26 2023-03-24 Cv6治疗(Ni)有限公司 与脱氧尿苷三磷酸酶抑制剂联合治疗
CN111763176A (zh) * 2020-07-10 2020-10-13 常州制药厂有限公司 一种GnRH受体拮抗剂关键中间体及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4341161A1 (de) 1993-12-02 1995-06-08 Michael Prof Dr Zeppezauer Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese
DK0763529T3 (da) * 1995-03-29 2003-11-10 Taiho Pharmaceutical Co Ltd Uracilderivater og antitumorvirkningspotentiator og antitumormiddel indeholdende samme
RU2102390C1 (ru) * 1996-06-06 1998-01-20 Научно-исследовательская лаборатория иммунохимиотерапии лепры и иммунотропных средств с клиникой и опытно-экспериментальным производством МЗМП России N-(6-метил-2,4-диоксо-1,2,3,4-тетрагидропиримидинил-5-сульфонил) пиразин-2-карбоксамид, обладающий противолепрозной, противотуберкулезной и иммунотропной активностью, способ его получения
JP2002028486A (ja) * 2000-07-14 2002-01-29 Toyobo Co Ltd アルデヒド類吸着分解剤及びその製造方法
JP2002284686A (ja) 2001-03-28 2002-10-03 Sankyo Co Ltd スルホンアミド化合物を含有する医薬組成物
AU2003218933A1 (en) 2002-04-17 2003-11-03 Affinium Pharmaceuticals, Inc. Purified dutpase from helicobacter pylori
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
JP4534122B2 (ja) * 2003-12-26 2010-09-01 トヨタ自動車株式会社 ハイブリッドシステム
GB0400290D0 (en) * 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
CN101495461A (zh) * 2006-07-24 2009-07-29 吉里德科学公司 新的hiv逆转录酶抑制剂
MY161094A (en) * 2009-11-30 2017-04-14 Taiho Pharmaceutical Co Ltd Anti-tumor effect potentiator

Also Published As

Publication number Publication date
KR101384940B1 (ko) 2014-04-11
BRPI0913590A2 (pt) 2015-10-20
TWI466871B (zh) 2015-01-01
ES2392220T3 (es) 2012-12-05
HK1154385A1 (en) 2012-04-20
US8530490B2 (en) 2013-09-10
EP2295414A4 (en) 2011-09-14
TW201000452A (en) 2010-01-01
KR20110013427A (ko) 2011-02-09
RU2010154425A (ru) 2012-07-20
MY149180A (en) 2013-07-31
AU2009254656A2 (en) 2011-01-13
CN102056905B (zh) 2014-03-26
MX2010013275A (es) 2011-03-15
CN102056905A (zh) 2011-05-11
CA2726579C (en) 2015-02-17
RU2495873C2 (ru) 2013-10-20
DK2295414T3 (da) 2012-10-22
CY1113244T1 (el) 2016-04-13
WO2009147843A1 (ja) 2009-12-10
PT2295414E (pt) 2012-11-30
AU2009254656B2 (en) 2013-07-18
HRP20120820T1 (hr) 2012-11-30
EP2295414B1 (en) 2012-09-26
BRPI0913590B1 (pt) 2021-07-06
EP2295414A1 (en) 2011-03-16
JPWO2009147843A1 (ja) 2011-10-27
JP4688975B2 (ja) 2011-05-25
AU2009254656A1 (en) 2009-12-10
US20110082163A1 (en) 2011-04-07
CA2726579A1 (en) 2009-12-10
SI2295414T1 (sl) 2012-12-31

Similar Documents

Publication Publication Date Title
SI2295414T1 (sl) Uracilna spojina, ki ima inhibitorno aktivnost za humano deoksiuridin-trifosfatazo, ali njena sol
EP2172453A4 (en) COMPOUND HAVING 11 ß-HSD1 INHIBITION ACTIVITY
IL205071A0 (en) Azolecarboxamide compound or salt thereof
HK1205005A1 (en) Bone treatment systems
IL210195A0 (en) Benzoxazines, benzothazines, and related compounds having nos inhibitory activity
GB0703417D0 (en) Electro-surgical systems
EP2065369A4 (en) UREA CONNECTION OR SALT THEREOF
EP2035077A4 (en) NON-INVASIVE NERVE STIMULATION SYSTEM
EP1854793A4 (en) NEW AMINOPYRIDEIN COMPOUND WITH SYK-HEMDERING EFFECT
EP2164561A4 (en) SYSTEMS, DEVICES AND METHODS ASSOCIATED WITH ENDOCARDIAL STIMULATION FOR RESYNCHRONIZATION
EP2231624A4 (en) TRIAZINE AND CORRESPONDING COMPOUNDS WITH ANTIVIRAL EFFECT, COMPOSITIONS AND METHOD THEREFOR
EP2426135A4 (en) UREA DERIVATIVE WITH PI3K-INHIBITING EFFECT
ZA201005210B (en) Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
HK1113746A1 (en) Solution for tissue adhesion prevention
GB0714029D0 (en) Lantibiotic-based compounds having antimicrobial activity
ZA200707227B (en) Novel aminopyridine compound with syk inhibitory activity
IL212403A0 (en) Carbamate compound or salt thereof
EP2149561A4 (en) TETRAHYDROISOCHINOLIN-1-ON DERIVATIVE OR SALT THEREOF
IL210316A0 (en) Triazole derivative or salt thereof
EP2168947A4 (en) NOVEL COMPOUND HAVING SECRETASE INHIBITING ACTIVITY
ZA201103269B (en) COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY
GB0606921D0 (en) Skin dressing
EP2017279A4 (en) NEW AMINO-PYRIDINE DERIVATIVE WITH AURORA A SELECTIVE HEMORATIVE EFFECT
GB0710260D0 (en) Otter predation defence system
PL380685A1 (pl) System mikroaktywacji skóry